Research programme: inflammatory bowel disease therapeutics - Boehringer Ingelheim

Drug Profile

Research programme: inflammatory bowel disease therapeutics - Boehringer Ingelheim

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Cinnamates
  • Mechanism of Action Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in USA
  • 10 Nov 2015 Boehringer Ingelheim and Icahn School of Medicine, Massachusetts General Hospital, The Scripps Research Institute and Weill Cornell Medicine agree to co-develop drug for inflammatory bowel disease in USA
  • 02 Sep 2008 Preclinical trials in Inflammatory bowel disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top